BENZOTEF (Benzotephum).
Benzoil-N N ', N-di (ethylene) - triamid phosphoric acid, or dietilenimid benzoilamidofosfornoy acid.
The white crystalline powder and odourless. Mg in the water (1:10), alcohol, chloroform. Aqueous solutions gidrolizuyutsya easily.
On antitumor activity and mechanism of action benzotef not significantly different from the other compounds containing group etilenimina (tiofosfamid, dipin etc.).
Applied with ovarian cancer, in particular astsitah, zabryushinnye metastases in lymph nodes and sealing with breast cancer (in the late stages and metastasized to the lungs and pleura vypotom defeat in the chest cavity), as well as other kartsinomatoznyh pleurisy and astsitah.
Enter intravenous dose of 0,024 g (24 mg) in 20 ml of sterile isotonic sodium chloride solution. Usually enter 3 times a week, as bad Portability (nausea, vomiting), the interval between a raise of 1 to 2 days. The course of treatment 15 - 20 placing. Patients who are having a blood platelets and rapidly decreasing, the number of introductions should be reduced. The course of treatment complete with a decrease in the number of leukocyte count to 3 x 10 9 / L, and platelets 100 x 10 9 / L.
In kartsinomatoznyh astsitah or pleurisy give drug dose 24 48 mg (20-40 ml) in the cavity after evacuation exudation.
Re-treatment can be carried out at 1 to 3 months, subject to reconstruct the blood.
A systematic treatment of haematological control. Benzotef sometimes better tolerated by the patients more than tiofosfamid, but he, like tiofosfamid could cause radiation and thrombocytopenia, and in high doses - pantsitopeniyu.
With the dramatic lowering of blood and platelets, a drug drop, enabling the number of blood transfusions or leykotsitnoy and trombotsitnoy mass designate leykopoeza stimulants. The drug can also cause nausea and vomiting; If necessary, designate these cases aminazin or other antiemetics drugs.
Benzotef contraindications to the concerns of cachexia, radiation (leykopitov less than 4 x 10 9 / L), a sharp anemia, with active tuberculosis, violations of liver and kidney functions, severe circulatory failure.
Product : potted in a hermetically sealed or ukuporennyh bottles containing 0,025 mg (25 mg) drug. Solutions are in a giving directly to the application.
Storage : List A. In the dark place at a temperature of not more than + 5 C.
|
||
Materials allowed to copy only with the active hyperlink to the handbook of medicines
|
||
